Aurobindo Pharma , a leading Indian pharmaceutical company, has announced a strategic move to restructure its biologics business. The company has entered into a binding agreement to transfer shares of Curateq Biologics, signaling a significant step in the verticalization of its biologics and biosimilars operations.

Key Points of the Transaction

• Agreement Date: July 29, 2025
• Parties Involved:
  • Helix Healthcare B.V. (transferor)
  • Curateq Biologics B.V. (transferee)
  • Curateq Biologics s.r.o. (company being transferred)
• Transaction Value: EUR 3,000,000 (approximately INR 303.00 million)
• Completion Deadline: August 31, 2025

Details of the Restructuring

Aurobindo Pharma has initiated this share transfer as part of its strategy to streamline its biologics business. The transaction involves the following wholly-owned subsidiaries of Aurobindo Pharma:

1. Helix Healthcare B.V. (The Netherlands): Currently holds 100% share capital of Curateq Biologics s.r.o.
2. Curateq Biologics B.V. (The Netherlands): Newly incorporated on May 28, 2025, as a wholly-owned subsidiary of Curateq Biologics Private Limited, India.
3. Curateq Biologics s.r.o. (Czech Republic): The company whose shares are being transferred.

Post-transaction, Curateq Biologics s.r.o. will become a wholly-owned subsidiary of Curateq Biologics B.V., aligning with Aurobindo's verticalization strategy for its biologics and biosimilars business.

Financial Snapshot

The following table provides a financial overview of the companies involved for the year ended March 31, 2025:

*Note: Curateq Biologics B.V. was incorporated on May 28, 2025, hence financial data is not available.

Regulatory Compliance

Aurobindo Pharma has confirmed that the transaction complies with all necessary regulations:

• No governmental or regulatory approvals are required for this acquisition.
• As per Section 188 of the Companies Act, 2013, and Regulation 23(5)(b) of the SEBI Listing Regulations, provisions related to related party transactions are not applicable as this transaction is between wholly-owned subsidiaries.

Impact and Objectives

The primary objective of this restructuring is to make Curateq Biologics s.r.o. a wholly-owned subsidiary of Curateq Biologics B.V. This move is part of Aurobindo Pharma's broader strategy to verticalize the biologics and biosimilars business under Curateq Biologics Private Limited.

While the immediate financial impact may be limited, as Curateq Biologics s.r.o. has not generated any turnover in the past three years, this restructuring positions Aurobindo Pharma for potential growth and operational efficiency in its biologics segment.

As the pharmaceutical landscape continues to evolve, Aurobindo Pharma's strategic restructuring of its biologics business demonstrates the company's commitment to strengthening its position in this high-potential sector.

Aurobindo Pharma , a leading Indian pharmaceutical company, has announced a significant restructuring move within its biologics business. The company has entered into a binding agreement to transfer shares of Curateq Biologics, signaling a strategic realignment of its subsidiaries.

Key Details of the Transaction

• Agreement Date: July 29, 2025
• Parties Involved:
  • Helix Healthcare B.V. (Transferor)
  • Curateq Biologics B.V. (Transferee)
  • Curateq Biologics s.r.o. (Company being transferred)
• Nature of Transaction: Transfer of 100% stake in Curateq Biologics s.r.o.
• Consideration: EUR 3,000,000 (approximately INR 303.00 million)
• Expected Completion: On or before August 31, 2025

Restructuring the Biologics Business

The share transfer is part of Aurobindo Pharma's efforts to verticalize its biologics and biosimilars business under CuraTeQ Biologics Private Limited, a wholly owned subsidiary of the company. This move is expected to streamline operations and potentially enhance the focus on the biologics segment.

About the Companies Involved

1. Helix Healthcare B.V. (The Netherlands)

• Wholly owned subsidiary of Aurobindo Pharma
• Net-worth: INR 29,317.40 million (as of March 31, 2025)

2. Curateq Biologics B.V. (The Netherlands)

• Incorporated on May 28, 2025
• Wholly owned subsidiary of CuraTeQ Biologics Private Limited, India

3. Curateq Biologics s.r.o. (Czech Republic)

• Incorporated on July 27, 2021
• Focused on marketing pharmaceutical products
• Net-worth: INR 207.40 million (as of March 31, 2025)

Financial Implications

The transaction is being undertaken among wholly owned subsidiaries of Aurobindo Pharma, resulting in no impact on a consolidated basis. It's worth noting that Curateq Biologics s.r.o. has not generated any turnover in the past three financial years, indicating it may still be in a developmental phase.

Regulatory Aspects

The company has stated that no governmental or regulatory approvals are required for this acquisition. As per Indian regulations, the provisions relating to related party transactions are not applicable in this case, as the transaction is between wholly owned subsidiaries.

This strategic move by Aurobindo Pharma underscores the company's focus on optimizing its corporate structure, particularly in the high-potential biologics and biosimilars segment. The restructuring could potentially lead to more efficient operations and better positioning of the company's biologics business in the global pharmaceutical market.